Rating Rationale
January 07, 2025 | Mumbai
UPL Limited
Ratings reaffirmed at 'CRISIL AA+/Negative/CRISIL A1+'
 
Rating Action
Total Bank Loan Facilities RatedRs.6400 Crore
Long Term RatingCRISIL AA+/Negative (Reaffirmed)
Short Term RatingCRISIL A1+ (Reaffirmed)
 
Rs.1100 Crore Commercial PaperCRISIL A1+ (Reaffirmed)
Note: None of the Directors on CRISIL Ratings Limited’s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its ‘CRISIL AA+/Negative/CRISIL A1+’ ratings on the bank facilities and commercial paper programme of UPL Limited (UPL).

 

UPL’s revenue grew 5% on-year in the first half of fiscal 2025, driven by volume growth across key geographies, majorly Brazil, India and the US. Production realisation remained under pressure owing to higher supply from China, impacting the operating profitability which slipped by 140 basis points (bps) to 12.2% in the first half of fiscal 2025. Furthermore, the operating profitability was also impacted by provisions for expected credit loss of Rs 134 crore ($ 13 million). The company’s performance is expected to be better in the second half of fiscal 2025 with the onset of cropping season in the US and Latin America (LatAm) supporting demand, and no further material decline anticipated in product realisation. Rationalization of channel stock in LatAm and the US markets, benefits of cost saving measures taken in the previous fiscal and new product launches (primarily differentiated products) will support the recovery in performance. UPL’s revenue is expected to grow by low to mid-single digits in fiscal 2025, while its operating profitability is expected at 14-15%, much lower than the 18-20% registered by the company up to fiscal 2023. An improvement to the earlier growth trajectory, in terms of revenue and operating profitability, is expected only from fiscal 2026.

 

In November 2023, the board’s approval was obtained for raising funds up to $ 500 million. In November 2024, UPL’s board finalized the fundraise of $ 400 million by equity rights issue. Out of the $ 400 million, $ 100 million of funds had been raised in December 2024 by way of partially paid rights shares. UPL will call the remaining $ 300 million in one or more tranches based on board approval. Furthermore, UPL’s board also approved divestment of 12.5% stake in Advanta Enterprise Ltd (AEL, rated ‘CRISIL AA+/Negative’) to the US-based private equity firm, Alpha Wave Ventures, for a total consideration of $ 350 million, which includes $ 250 million for secondary sale of shares by UPL and $ 100 million primary infusion in AEL. Post the divestment, UPL will hold 74.7% stake in AEL. Majority of the proceeds from the rights issue and divestment of stake in AEL will be deployed towards debt reduction.

 

Gross debt declined to Rs 31,843 crore as on September 30, 2024 (from Rs 33,934 crore as on September 30, 2023) despite lower factoring in the first half of fiscal 2025, due to tight control over working capital supported by inventory optimisation and tightened credit period with UPL realigning its strategy to place the products closer to application. The debt increased in fiscal 2024 owing to industry headwinds with ratio of net debt to earnings before interest, taxes, depreciation and amortisation (Ebitda) increasing to 5.3 times in fiscal 2024 compared with less than 2 times till fiscal 2023. The capital expenditure (capex) will be moderate at Rs 2,000-2,500 crore per annum, over the medium term, which will be met by cash accruals. With the improvement in profitability, tight control over working capital, proceeds from rights issue and divestment of stake in AEL, the net debt to Ebitda ratio is expected to be below 3 times in fiscal 2025, considering the $ 100 million to be raised in December 2024 through rights issue and the $ 250 million of divestment proceeds to be deployed towards debt reduction. With further improvement in performance and raising of the balance $ 300 million rights issue proceeds, the net debt to Ebitda ratio will improve to 2.0-2.2 times over the medium term.

 

Delay in the recovery of operating performance, stretch in the working capital cycle or lower-than-expected fundraise, and consequent high debt will result in a rating downgrade.

 

UPL does not have principal repayment obligations until August 2025. However, it has sizeable debt obligation of Rs 6,255 crore in the second half of fiscal 2026, and Rs 7,506 crore in fiscal 2027 which will require part refinancing. Besides, the company’s perpetual bonds will also come up for repricing at prevalent market rates in May 2025 and UPL will have an option to call the bonds starting from February 2025. Refinancing of these bonds will push up interest costs, as current rates are much higher than interest rates prevalent about five years ago, when these bonds were raised. Timely refinancing of debt obligation, including raising new debt with extended maturity, will remain critical.

 

The ratings continue to reflect the UPL’s strong business risk profile supported by robust market position, wide product portfolio, geographical diversification in revenue and adequate operating efficiencies. These strengths are partially offset by the average financial risk profile, which has moderated from its strong position owing to moderation in operational performance but is expected to gradually improve in the near to medium term; the company’s large working capital requirement and susceptibility to risks inherent in the agrochemical sector.

Analytical Approach

To arrive at its ratings, CRISIL Ratings has combined the business and financial risk profiles of UPL and its subsidiaries, collectively known as UPL. This is because all these companies are under a common management and have close operational linkages and fungible cash flows. CRISIL Ratings follows a moderate integration approach for investment in associates and joint ventures in which UPL has significant influence but not a controlling interest—specifically, CRISIL Ratings factored in UPL's share in the profit of these entities and any incremental investment required.

 

Goodwill on the acquisition of Arysta which as acquired in fiscal 2019 is being amortised over a period of 15 years commencing from fiscal 2019. Consequently, reported profit after tax (PAT), networth and ratio computations are adjusted.

 

USD-denominated Perpetual Subordinated Capital Securities (bonds) of $ 400 million (interest coupon rate of 5.25% per annum) raised by UPL Corporation Ltd (subsidiary of UPL) has been treated as 50% debt and 50% equity.

 

Non-recourse factoring of receivables has not been treated as debt.

 

Please refer to Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description

Strengths:

Large scale with diverse geographical presence: UPL is among the top five players in the global agrochemicals industry. The revenue base is well diversified, with ~70% generated from LatAm, Europe and North America. Wider geographical reach reduces susceptibility to cyclicality in demand from any one region. The company is also the largest agrochemical player in the domestic market, which contributed less than 15% to its turnover in fiscal 2024. UPL has grown through inorganic acquisitions over the years, the largest being that of Arysta, which strengthened its position as a leading global agrochemical player.

 

Wide product portfolio: UPL is also present across the crop lifecycle, from seeds, seed-treatment products, pre- and post-harvest products to storage-treatment products. This ensures lower business volatility compared to peers with a less diversified portfolio. The business risk profile remains healthy, aided by a portfolio of ~14,326 registrations, 1,552 product formulations and 1,500 patents. UPL is present in 138 countries with 42 manufacturing locations, employing more than 13,000 people across the globe.

 

Adequate operating efficiencies, supporting profitability: Backward integration and supply-chain management have strengthened operating efficiencies, which along with steady revenue growth translated into healthy operating profitability of 19-21% between fiscals 2018 and 2023. As a sizeable portion of raw material and power requirement is met in-house, the group is assured a steady supply, with less price volatility. Flexible and multi-product manufacturing facilities, and robust supply chain and distribution network support its profitability.

 

However, sluggish offtake and pricing pressure exacerbated by cheap Chinese supplies, have forced most industry players, including UPL, to offer rebates, impacting realisations and operating profitability in fiscal 2024. With the write-down of inventories, lower rebates with selling closer to season, and demand picking up gradually, the operating profitability of UPL is expected to increase to 14-15% in fiscal 2025, from 10.5% in fiscal 2024. Further improvement in the operating profitability is expected over the medium term, due to better demand and the intrinsic strength of UPL’s established product.

 

Weaknesses:

Large working capital requirement: The crop protection business is seasonal in nature. Sales occur at the start of the season, but payment is realised post-harvest, resulting in stretched receivables cycle. Furthermore, as goods are manufactured in one place and distributed to other locations, a sizeable stock of finished goods needs to be maintained. The large credit required by customers in key LatAm markets also leads to a stretch in the working capital cycle. However, UPL will contain the exposure to markets with long credit cycle to less than one-third of its revenue and utilize securitization benefits (without recourse) wherever available, thereby mitigating the impact of a stretched cycle on the overall credit profile.

 

Average financial risk profile: UPL’s financial risk profile is supported by sizeable estimated networth of over Rs 25,500 crore as on March 31, 2025. The acquisition of Arysta in fiscal 2019 was funded through substantial debt (~$ 3 billion), which led to gross debt of ~Rs 29,000 crore as on March 31, 2019, and resulted in moderation in the debt protection metrics. Debt peaked at ~Rs 30,200 crore as on March 31, 2020, and thereafter reduced by ~Rs 5,000 crore in fiscal 2021, supported by strong operational cash generation and partial pre-payment. The gross debt then increased by ~Rs 2,500 crore in fiscal 2022, mainly on account of higher working capital requirement and then declined by Rs 2,880 crore to Rs 24,379 crore at the end of fiscal 2023, supported by cash flow from stake sale in some of its businesses, and increase in non- recourse factoring.

 

While the debt was expected to reduce further due to prudent capex spend, gross debt increased to Rs 29,331 crore at end of fiscal 2024 due to modest cash generation, stretched working capital cycle and reduced non-recourse factoring. Due to modest performance in fiscal 2024, net debt to Ebitda and interest coverage ratios were 5.3 times and 1.2 times, respectively, compared to below 2 times and 3.6 times, respectively, in fiscal 2023. With improved cash generation due to better performance and improvement in the working capital cycle, and proceeds from the rights issue and divestment, the net debt to Ebitda ratio is expected to decline below 3 times in fiscal 2025. With improvement in performance and further raising of remaining funds through rights issue, the net debt to Ebitda ratio is expected to decline to 2.00–2.25 times by fiscal 2026.

 

UPL Corporation’s minority investors, ADIA and TPG, each with ~11% stake, who had invested in UPL Corporation to support the acquisition of Arysta have the option to sell their stakes, to which UPL has the right of first refusal. These stakes have now moved to UPL Ltd, Cayman under the recent restructuring. While the stake sale is unlikely in the next 1-2 years, any material debt addition by UPL to buy back these stakes in UPL Ltd, Cayman from these investors, and consequent increase in its leverage will be monitorable.

 

Susceptibility to risks inherent in the agrochemicals sector: The crop protection sector remains susceptible to specific and separate registration processes in different countries, and to various environmental rules and regulations. Changes in regulatory requirements such as export and import policies, and environmental and safety requirements in countries where the company has significant exposure, could weaken the growth prospects. Furthermore, the sector is highly dependent on monsoon and the level of farm income. Hence, timing and distribution of rainfall during a year plays a crucial role. This is somewhat mitigated by the geographically diverse base of UPL.

Liquidity: Strong

Cash and equivalents were at Rs 4,312 crore as on September 30, 2024. The utilisation of domestic fund-based working capital limits was moderate at 70% (of total drawing power) on average for the six months through November 2024. The annual capex of Rs 2,000-2,500 crore is expected to be funded by internal accrual and no long-term debt addition is expected. Cash accrual will be Rs 3,500-4,000 crore in fiscal 2025 and increase to Rs 4,000-5,000 crore per annum over the medium term.

 

UPL does not have any material long-term debt obligation till August 2025. However, the company has debt obligation of Rs 6,000–7,000 crore in the second half of fiscal 2026 and in fiscal 2027, which will necessitate partial refinancing. Besides, the company’s perpetual bonds will come up for repricing at prevalent market rates in May 2025, which are much higher at present, and can result in slightly higher interest outgo on these bonds. UPL will also have the option to call the perpetual bonds in February 2025.

 

CRISIL Ratings expects UPL to be able to refinance the required portion of their obligation, given past instances of successfully arranging for similar refinancing, ahead of actual repayment.

 

ESG profile of UPL

CRISIL Ratings believes that UPL’s ESG profile supports its already strong credit risk profile.

The agrochemical sector has a high impact on the environment because of high greenhouse gas (GHG) emissions, water use and high hazardous waste generation by its core operations. The sector has a social impact because of its large workforce and has an impact on the health and well-being of its workers and local community on account of the nature of operations.

 

UPL has undertaken various initiatives and efforts towards mitigating its environmental and social impact and strengthening its ESG profile. 

 

Key ESG highlights:

  • UPL has consistently invested in reducing GHG, with focus on reducing carbon footprint in manufacturing and decarbonising through sustainable products. Investing in renewable energy is helping UPL to reduce carbon dioxide (CO2) equivalent emissions by 1.25 lakh tonne per year.
  • UPL has reduced its water consumption in its plants by 40% over the past three years, driven by active investments to reduce its water footprint. UPL became the first agrochemical company to make its technical manufacturing facility zero liquid discharge (ZLD). Now ~60% of UPL’s plants have achieved ZLD.
  • UPL has significantly increased its renewable energy usage, accounting for 30% of total global power consumption. The solar-wind hybrid farm has an impressive capacity of 61 megawatt (MW), comprising 33 MW of wind and 28 MW of solar, which will be set up in collaboration with CleanMax.
  • UPL targets to achieve at least 60% of sustainable sourcing by 2025, compared with 30% at present.
  • UPL’s governance structure is characterised by the majority of its board comprising independent directors, and extensive disclosures.

 

There is growing importance of ESG among investors and lenders. The commitment of UPL to ESG principles will play a key role in enhancing stakeholder confidence, given the high share of market borrowing in its overall debt and access to both domestic and foreign capital markets.

Outlook: Negative

CRISIL Ratings believes that the performance of UPL will improve gradually over the medium term, with the revival in demand for agrochemicals in the domestic and international markets benefitting the operating profitability and cash generation, which will remain below earlier expectations. Progressive debt reduction, including through proposed rights issue of equity, will be critical to improve the debt protection metrics, which are at elevated levels.

Rating sensitivity factors

Upward factors

  • Better-than-expected growth in revenue, with operating profitability at 21-22%, ensuring strong cash generation
  • Net debt to Ebitda ratio sustaining at 1.00-1.25 times, due to strong cash generation and lower debt due to prudent working capital management or equity infusion

 

Downward factors

  • Continued demand sluggishness due to delay in revival of demand for agrochemicals, and operating profitability remaining below 15%, further impacting cash generation
  • Net debt to Ebitda ratio remaining at 2.35-2.50 times on sustained basis and interest coverage ratio remaining sub-par, due to delay in equity raise, more-than-anticipated capex, material acquisitions and stretched working capital cycle, or due to increased stake in UPL Ltd, Cayman, leading to high debt

About the Company

Incorporated in 1969 and promoted by Mr Rajnikant Shroff, UPL manufactures, markets and distributes crop protection products, intermediates, speciality chemicals and other industrial chemicals; and undertakes research in these segments. Over time, UPL has made several acquisitions and entered strategic alliances to diversify its product profile and increase geographical reach. UPL now includes over 200 entities. Apart from UPL, the other key operating companies in the group are UPL NA Inc (US), UPL Europe Ltd (UK), UPL Agro SA DE CV (Mexico), UPL Argentina SA (Argentina), UPL France, UPL Italia SRL, UPL South Africa PTY Ltd and UPL do Brasil Industria e Comercio de SA (Brazil). UPL group has manufacturing units in India, France, Argentina, the UK, Vietnam, Turkey, Brazil, the USA, China, Thailand, Italy, Australia and Columbia.

Key Financial Indicators

Particulars for year ending March 31

Unit

2024

2023

Revenue

Rs crore

42,915

53,520

Adjusted PAT^

Rs crore

(2988)

3304

PAT margin^

%

-7.0

6.2

Adjusted debt/adjusted networth^

Times

1.24

0.93

 Adjusted interest coverage

Times

1.21

3.61

^CRISIL Ratings-adjusted numbers for treatment of goodwill

Any other information: Not Applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

CRISIL Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the CRISIL Ratings` complexity levels please visit www.crisilratings.com. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN Name Of Instrument Date Of Allotment Coupon Rate (%) Maturity Date Issue Size (Rs.Crore) Complexity Levels Rating Outstanding with Outlook
NA Commercial Paper NA NA 7 to 365 Days 300.00 Simple CRISIL A1+
NA Commercial Paper NA NA 7 to 365 Days 800.00 Simple CRISIL A1+
NA Cash Credit# NA NA NA 1029.00 NA CRISIL AA+/Negative
NA Fund-Based Facilities* NA NA NA 4139.00 NA CRISIL AA+/Negative
NA Letter of credit & Bank Guarantee NA NA NA 597.00 NA CRISIL A1+
NA Proposed Working Capital Facility** NA NA NA 635.00 NA CRISIL AA+/Negative

#Fully interchangeable between cash credit, working capital demand loan, foreign currency non-resident (bank) loans, packing credit in INR, packing credit in foreign currency, export bill discounting in INR and foreign currency, buyer's credit for imports and domestic purchases, and domestic sales bill discounting. It can also be converted into non-fund-based facilities.
*Fully interchangeable with non-fund based facilities
**It can be converted into non-fund-based facilities.

Annexure – List of entities consolidated

Names of entities consolidated

Extent of Consolidation

Rationale for Consolidation

UPL Global Business Services Ltd (FKA Shroffs United Chemicals Ltd)

Full

Wholly owned subsidiary

SWAL Corporation Ltd

Full

Wholly owned subsidiary

United Phosphorus (India) LLP

Full

Wholly owned subsidiary

United Phosphorus Global LLP

Full

Wholly owned subsidiary

UPL Sustainable Agri Solutions Ltd (FKA Optima Farm Solutions Ltd)

Full

Wholly owned subsidiary

UPL Europe Ltd

Full

Subsidiary

United Phosphorus Polska Sp.z o.o - Poland

Full

Subsidiary

UPL Benelux B.V.

Full

Subsidiary

Cerexagri B.V.

Full

Subsidiary

UPL Holdings Cooperatief U.A (FKA United Phosphorus Holdings Cooperatief U.A.)

Full

Subsidiary

UPL Holdings BV (FKA United Phosphorus Holdings B.V., Netherlands)

Full

Subsidiary

Decco Worldwide Post-Harvest Holdings Cooperatief U.A.

Full

Subsidiary

Decco Worldwide Post-Harvest Holdings B.V.

Full

Subsidiary

UPL Holdings Brazil B.V. (FKA United Phosphorus Holding, Brazil B.V.)

Full

Subsidiary

UPL Italia S.R.L.

Full

Subsidiary

UPL Iberia, S.A.

Full

Subsidiary

Decco Iberica Postcosecha, S.A.U.

Full

Subsidiary

Transterra Invest, S. L. U.

Full

Subsidiary

Cerexagri S.A.S.

Full

Subsidiary

UPL France

Full

Subsidiary

UPL Switzerland AG (formerly known as United Phosphorus Switzerland Ltd)

Full

Subsidiary

Decco Italia SRL

Full

Subsidiary

Limited Liability Company "UPL"

Full

Subsidiary

Decco Portugal Post Harvest LDA (formerly known as UPL Portugal Unipessoal LDA)

Full

Subsidiary

UPL NA Inc. (formerly known as United Phosphorus Inc.)

Full

Subsidiary

Cerexagri, Inc. (PA)

Full

Subsidiary

UPL Delaware, Inc.

Full

Subsidiary

Decco US Post-Harvest Inc

Full

Subsidiary

RiceCo LLC

Full

Subsidiary

Riceco International, Inc

Full

Subsidiary

UPL Corporation Ltd

Full

Subsidiary

UPL Management DMCC

Full

Subsidiary

UPL Ltd

Full

Subsidiary

UPL Agro S.A. de C.V.

Full

Subsidiary

Decco PostHarvest Mexico (formerly known as Decco Jifkins Mexico Sapi)

Full

Subsidiary

Uniphos Industria e Comercio de Produtos Quimicos Ltda.

Full

Subsidiary

Upl do Brasil Industria e Comércio de Insumos Agropecuários S.A.

Full

Subsidiary

UPL Costa Rica S.A.

Full

Subsidiary

UPL Bolivia S.R.L

Full

Subsidiary

UPL Paraguay S.A.

Full

Subsidiary

UPL SL Argentina S.A. (Formerly Known as Icona Sanluis S A)

Full

Subsidiary

UPL Argentina S A

Full

Subsidiary

Decco Chile SpA

Full

Subsidiary

UPL Colombia SAS

Full

Subsidiary

United Phosphorus Cayman Ltd

Full

Subsidiary

UP Aviation Ltd

Full

Subsidiary

UPL Australia Pty Ltd (formerly known as UPL Austarlia Ltd)

Full

Subsidiary

UPL Shanghai Ltd

Full

Subsidiary

PT.UPL Indonesia

Full

Subsidiary

PT Catur Agrodaya Mandiri

Full

Subsidiary

UPL Ltd, Hong Kong (formerly known as United Phosphorus Ltd, Hongkong)

Full

Subsidiary

UPL Philippines Inc

Full

Subsidiary

UPL Vietnam Co Ltd

Full

Subsidiary

UPL Japan GK (formerly known as UPL Ltd, Japan)

Full

Subsidiary

Anning Decco Fine Chemical Co Ltd

Full

Subsidiary

UPL Ziraat Ve Kimya Sanayi Ve Ticaret Ltd Sirketi

Full

Subsidiary

UPL Agromed Tohumculuk Sa,Turkey

Full

Subsidiary

Decco Israel Ltd (formerly known as Safepack Products Ltd)

Full

Subsidiary

Citrashine (Pty) Ltd

Full

Subsidiary

Prolong Ltd

Full

Subsidiary

Perrey Participações S.A

Full

Subsidiary

Advanta Netherlands Holding B.V.

Full

Subsidiary

Advanta Semillas SAIC

Full

Subsidiary

Advanta Holdings B.V.

Full

Subsidiary

Advanta Seeds International

Full

Subsidiary

Pacific Seeds Holdings (Thailand) Ltd

Full

Subsidiary

Pacific Seeds (Thai) Ltd

Full

Subsidiary

Advanta Seeds Pty Ltd

Full

Subsidiary

Advanta US LLC (formerly known as Advanta U.S. Inc)

Full

Subsidiary

Advanta Comercio De Sementes LTDA

Full

Subsidiary

PT Advanta Seeds Indonesia

Full

Subsidiary

Advanta Seeds DMCC

Full

Subsidiary

UPL Ltd Mauritius (formerly known as UPL Agro Ltd Mauritius)

Full

Subsidiary

UPL Jiangsu Ltd

Full

Subsidiary

Riceco International Bangladesh Ltd

Full

Subsidiary

Uniphos Malaysia Sdn Bhd

Full

Subsidiary

Advanta Seeds Ukraine LLC

Full

Subsidiary

Decco Gida Tarim ve Zirai Ürünler San. Tic A.S.

Full

Subsidiary

Arysta LifeScience America Inc

Full

Subsidiary

Arysta LifeScience Management Company, LLC

Full

Subsidiary

Arysta LifeScience India Ltd

Full

Subsidiary

Arysta LifeScience Agriservice Pvt Ltd

Full

Subsidiary

UPL Togo SAU (FKA Arysta LifeScience Togo SAU)

Full

Subsidiary

Arysta Agro Pvt Ltd

Full

Subsidiary

GBM USA LLC

Full

Subsidiary

UPL Agrosolutions Canada Inc (formerly known as Arysta LifeScience Canada, Inc)

Full

Subsidiary

Arysta LifeScience North America, LLC

Full

Subsidiary

Arysta LifeScience NA Holding LLC

Full

Subsidiary

Arysta LifeScience Inc

Full

Subsidiary

Arysta LifeScience Services LLP

Full

Subsidiary

Arysta LifeScience Benelux SPRL

Full

Subsidiary

Arysta LifeScience (Mauritius) Ltd

Full

Subsidiary

UPL South Africa (Pty) Ltd (formerly known as Arysta LifeScience South Africa (Pty) Ltd)

Full

Subsidiary

Arysta Health and Nutrition Sciences Corporation

Full

Subsidiary

Arysta LifeScience Corporation

Full

Subsidiary

Arysta LifeScience S.A.S.

Full

Subsidiary

Arysta LifeScience Chile S.A.

Full

Subsidiary

Arysta LifeScience Mexico, S.A.de C.V

Full

Subsidiary

Grupo Bioquimico Mexicano, S.A. de C.V.

Full

Subsidiary

Arysta LifeScience UK & Ireland Ltd

Full

Subsidiary

UPL Agricultural Solutions (formerly known as MacDermid Agricultural Solutions Italy Srl)

Full

Subsidiary

UPL Europe Supply Chain GmbH (formerly known as Platform Sales Suisse GmbH)

Full

Subsidiary

UPL Agricultural Solutions Holdings BV (formerly known as MacDermid Agricultural Solutions Holdings BV)

Full

Subsidiary

Netherlands Agricultural Investment Partners LLC

Full

Subsidiary

UPL Bulgaria EOOD (FKA Arysta LifeScience Bulgaria EOOD)

Full

Subsidiary

UPL Agricultural Solutions Romania SRL (FKA Arysta LifeScience Romania SRL)

Full

Subsidiary

Arysta LifeScience Great Britain Ltd

Full

Subsidiary

Arysta LifeScience Netherlands BV

Full

Subsidiary

Arysta LifeScience RUS LLC

Full

Subsidiary

Arysta LifeScience Australia Pty Ltd.

Full

Subsidiary

Arysta-LifeScience Ecuador S.A.

Full

Subsidiary

Arysta LifeScience Ougrée Production Sprl

Full

Subsidiary

UPL Hellas S.A. (formerly known as Arysta LifeScience Hellas S.A. Plant Protection, Nutrition and Other Related Products and Services)

Full

Subsidiary

Naturagri Soluciones, SLU (formerly known as Arysta LifeScience Iberia SLU)

Full

Subsidiary

Arysta LifeScience Switzerland Sarl

Full

Subsidiary

Vetophama SAS (formerly known as Arysta Animal Health SAS)

Full

Subsidiary

Sci PPWJ

Full

Subsidiary

Vetopharma Iberica SL (formerly known as Santamix Iberica SL, Spain)

Full

Subsidiary

United Phosphorus Global Services Ltd (FKA Arysta LifeScience Global Services Ltd)

Full

Subsidiary

Arysta LifeScience European Investments Ltd

Full

Subsidiary

Arysta LifeScience U.K. Ltd

Full

Subsidiary

Arysta LifeScience U.K. CAD Ltd

Full

Subsidiary

Arysta LifeScience U.K. EUR Ltd

Full

Subsidiary

Arysta LifeScience U.K. JPY Ltd

Full

Subsidiary

Arysta LifeScience U.K. USD Ltd

Full

Subsidiary

Arysta Lifescience U.K. Holdings Ltd

Full

Subsidiary

Arysta LifeScience Japan Holdings Goudou Kaisha

Full

Subsidiary

Arysta LifeScience Cameroun SA

Full

Subsidiary

Callivoire SGFD S.A.

Full

Subsidiary

UPL Egypt Ltd (formerly known as Arysta LifeScience Egypt Ltd)

Full

Subsidiary

Calli Ghana Ltd

Full

Subsidiary

Arysta LifeScience Kenya Ltd

Full

Subsidiary

Mali Protection Des Cultures (M.P.C.) SA

Full

Subsidiary

Agrifocus Limitada

Full

Subsidiary

UPL Holdings SA (Pty) Ltd (FKA Arysta LifeScience Holdings SA (Pty) Ltd)

Full

Subsidiary

Anchorprops 39 (Pty) Ltd

Full

Subsidiary

Sidewalk Trading (Pty) Ltd

Full

Subsidiary

Volcano Agroscience (Pty) Ltd

Full

Subsidiary

UPL (T) Ltd (formerly known as Arysta LifeScience Tanzania Ltd)

Full

Subsidiary

Pt. Arysta LifeScience Tirta Indonesia

Full

Subsidiary

UPL Limited Korea (FKA Arysta LifeScience Korea Ltd.)

Full

Subsidiary

Arysta LifeScience Pakistan (Pvt.) LTD

Full

Subsidiary

Arysta LifeScience Philippines Inc

Full

Subsidiary

Arysta LifeScience Asia Pte., Ltd

Full

Subsidiary

Arysta LifeScience (Thailand) Co, Ltd

Full

Subsidiary

Arysta LifeScience Vietnam Co, Ltd

Full

Subsidiary

Laboratoires Goëmar SAS

Full

Subsidiary

UPL Czech s.r.o. (FKA Arysta LifeScience Czech s.r.o.)

Full

Subsidiary

UPL Deutschland GmbH, (formerly known as Arysta LifeScience Germany GmbH)

Full

Subsidiary

UPL Hungary Kereskedelmi és Szolgáltató Korlátolt Felelosségu Társaság. (FKA Arysta LifeScience Magyarorszag Kft.)

Full

Subsidiary

UPL Polska Sp. z.o.o (formerly known as Arysta LifeScience Polska Sp. z.o.o)

Full

Subsidiary

Betel Reunion S.A.

Full

Subsidiary

Arysta LifeScience Vostok Ltd

Full

Subsidiary

UPL Slovakia S.R.O (FKA Arysta LifeScience Slovakia S.R.O.)

Full

Subsidiary

UPL Ukraine LLC (FKA Arysta LifeScience Ukraine LLC)

Full

Subsidiary

UPL Global Ltd (formerly known as Arysta LifeScience Global Limited)

Full

Subsidiary

Arysta LifeScience Colombia S.A.S

Full

Subsidiary

Arysta LifeScience CentroAmerica, S.A.

Full

Subsidiary

Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V.

Full

Subsidiary

Omega Agroindustrial, S.A. de C.V.

Full

Subsidiary

Servicios Agricolas Mundiales SA de CV

Full

Subsidiary

Arysta LifeScience Paraguay S.R.L.

Full

Subsidiary

Arysta LifeScience Peru S.A.C

Full

Subsidiary

Arysta LifeScience Costa Rica SA.

Full

Subsidiary

Arysta LifeScience de Guatemala, S.A.

Full

Subsidiary

Arysta LifeScience S.R.L.

Full

Subsidiary

Myanmar Arysta LifeScience Co., Ltd

Full

Subsidiary

Arysta LifeScience U.K. BRL Ltd

Full

Subsidiary

UPL New Zealand Ltd (FKA Etec Crop Solutions Ltd)

Full

Subsidiary

MacDermid Agricultural Solutions Australia Pty Ltd

Full

Subsidiary

Arysta LifeScience Registrations Great Britain Ltd

Full

Subsidiary

Industrias Agriphar SA

Full

Subsidiary

Agripraza Ltda.

Full

Subsidiary

Arysta LifeScience Corporation Republica Dominicana, SRL

Full

Subsidiary

Grupo Bioquimico Mexicano Republica Dominicana SA

Full

Subsidiary

Arvesta Paraguay S.A.

Full

Subsidiary

Arysta Agroquimicos y Fertilzantes Uruguay SA

Full

Subsidiary

Arysta LifeScience U.K. USD-2 Ltd

Full

Subsidiary

Industrias Bioquim Centroamericana, Sociedad Anónima

Full

Subsidiary

Bioquim Panama, Sociedad Anónima

Full

Subsidiary

UPL Nicaragua, Sociedad Anónima (FKA Bioquim Nicaragua, Sociedad Anónima)

Full

Subsidiary

Biochemisch Dominicana, Sociedad De Responsabilidad Limitada

Full

Subsidiary

Nutriquim De Guatemala, Sociedad Anónima

Full

Subsidiary

UPL Agro Ltd

Full

Subsidiary

UPL Portugal Unipessoal, Ltda.

Full

Subsidiary

UPL Services LLC

Full

Subsidiary

United Phosphorus Holdings Uk Ltd

Full

Subsidiary

Nurture Agtech Pvt Ltd. (FKA AFS Agtech Pvt. Limited)

Full

Wholly owned subsidiary

Natural Plant Protection Ltd

Full

Subsidiary

Advanta Biotech General Trading Ltd

Full

Subsidiary

UPL Mauritius Ltd

Full

Subsidiary

Hannaford Nurture Farm Exchange Pty Ltd

Full

Subsidiary

UPL Zambia Ltd

Full

Subsidiary

INGEAGRO S.A

Full

Subsidiary

Laoting Yoloo Bio-Technology Co Ltd

Full

Subsidiary

Decco Holdings UK Ltd

Full

Subsidiary

Advanta Seeds Holdings UK Ltd

Full

Subsidiary

Advanta Holdings US Inc

Full

Subsidiary

UPL Crop Protection Investments UK Ltd

Full

Subsidiary

UBDS COMERCIO DE PRODUTOS AGROPECUARIOS S.A

Full

Subsidiary

UPL Investments Southern Africa Pty Ltd

Full

Subsidiary

UPL Ltd, Cayman

Full

Subsidiary

UPL Health & Nutrition Science Holdings Ltd

Full

Subsidiary

UPL Animal Health Holdings Ltd

Full

Subsidiary

UPL Investments UK Ltd

Full

Subsidiary

PT Excel Meg Indo

Full

Subsidiary

PT Ace Bio Care

Full

Subsidiary

Annexure - Rating History for last 3 Years
  Current 2025 (History) 2024  2023  2022  Start of 2022
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 5803.0 CRISIL AA+/Negative   -- 13-06-24 CRISIL AA+/Negative 31-08-23 CRISIL AA+/Stable 19-12-22 CRISIL AA+/Stable CRISIL AA+/Stable
      --   -- 06-03-24 CRISIL AA+/Negative 07-07-23 CRISIL AA+/Stable 15-06-22 CRISIL AA+/Stable CRISIL AA+/Stable
      --   --   -- 28-03-23 CRISIL AA+/Stable   -- --
Non-Fund Based Facilities ST 597.0 CRISIL A1+   -- 13-06-24 CRISIL A1+ 31-08-23 CRISIL A1+ 19-12-22 CRISIL A1+ CRISIL A1+
      --   -- 06-03-24 CRISIL A1+ 07-07-23 CRISIL A1+ 15-06-22 CRISIL A1+ --
      --   --   -- 28-03-23 CRISIL A1+   -- --
Commercial Paper ST 1100.0 CRISIL A1+   -- 13-06-24 CRISIL A1+ 31-08-23 CRISIL A1+ 19-12-22 CRISIL A1+ CRISIL A1+
      --   -- 06-03-24 CRISIL A1+ 07-07-23 CRISIL A1+ 15-06-22 CRISIL A1+ --
      --   --   -- 28-03-23 CRISIL A1+   -- --
Non Convertible Debentures LT   --   --   --   --   -- Withdrawn
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Cash Credit# 282 Bank of Baroda CRISIL AA+/Negative
Cash Credit# 114 Kotak Mahindra Bank Limited CRISIL AA+/Negative
Cash Credit# 243 State Bank of India CRISIL AA+/Negative
Cash Credit# 100 Canara Bank CRISIL AA+/Negative
Cash Credit# 97 Union Bank of India CRISIL AA+/Negative
Cash Credit# 68 IDBI Bank Limited CRISIL AA+/Negative
Cash Credit# 50 ICICI Bank Limited CRISIL AA+/Negative
Cash Credit# 75 Axis Bank Limited CRISIL AA+/Negative
Fund-Based Facilities* 850 JP Morgan Chase Bank N.A. India CRISIL AA+/Negative
Fund-Based Facilities* 976 Citibank N. A. CRISIL AA+/Negative
Fund-Based Facilities* 1060 MUFG Bank CRISIL AA+/Negative
Fund-Based Facilities* 1060 Sumitomo Mitsui Banking Corporation CRISIL AA+/Negative
Fund-Based Facilities* 193 Deutsche Bank CRISIL AA+/Negative
Letter of credit & Bank Guarantee 97 IDBI Bank Limited CRISIL A1+
Letter of credit & Bank Guarantee 23 Canara Bank CRISIL A1+
Letter of credit & Bank Guarantee 75 ICICI Bank Limited CRISIL A1+
Letter of credit & Bank Guarantee 122 State Bank of India CRISIL A1+
Letter of credit & Bank Guarantee 43 Union Bank of India CRISIL A1+
Letter of credit & Bank Guarantee 69 Axis Bank Limited CRISIL A1+
Letter of credit & Bank Guarantee 129 Bank of Baroda CRISIL A1+
Letter of credit & Bank Guarantee 39 Kotak Mahindra Bank Limited CRISIL A1+
Proposed Working Capital Facility** 635 Not Applicable CRISIL AA+/Negative
#Fully interchangeable between cash credit, working capital demand loan, foreign currency non-resident (bank) loans, packing credit in INR, packing credit in foreign currency, export bill discounting in INR and foreign currency, buyer's credit for imports and domestic purchases, and domestic sales bill discounting. It can also be converted into non-fund-based facilities.
*Fully interchangeable with non-fund based facilities
**It can be converted into non-fund-based facilities.
Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for Chemical Industry
CRISILs Criteria for rating short term debt
CRISILs Criteria for Consolidation

Media Relations
Analytical Contacts
Customer Service Helpdesk

Ramkumar Uppara
Media Relations
CRISIL Limited
M: +91 98201 77907
B: +91 22 3342 3000
ramkumar.uppara@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Sanjay Lawrence
Media Relations
CRISIL Limited
M: +91 89833 21061
B: +91 22 3342 3000
sanjay.lawrence@crisil.com


Anuj Sethi
Senior Director
CRISIL Ratings Limited
B:+91 44 6656 3100
anuj.sethi@crisil.com


Poonam Upadhyay
Director
CRISIL Ratings Limited
B:+91 22 3342 3000
poonam.upadhyay@crisil.com


Sree Sankar
Manager
CRISIL Ratings Limited
B:+91 44 6656 3100
Sree.Madhu@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited, an S&P Global Company)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).

CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").

For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a leading, agile and innovative global analytics company driven by its mission of making markets function better. 

It is India’s foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') provided by CRISIL Ratings Limited ('CRISIL Ratings'). For the avoidance of doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for use only within the jurisdiction of India. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings provision or intention to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

The report is a statement of opinion as on the date it is expressed, and it is not intended to and does not constitute investment advice within meaning of any laws or regulations (including US laws and regulations). The report is not an offer to sell or an offer to purchase or subscribe to any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way.

CRISIL Ratings and its associates do not act as a fiduciary. The report is based on the information believed to be reliable as of the date it is published, CRISIL Ratings does not perform an audit or undertake due diligence or independent verification of any information it receives and/or relies on for preparation of the report. THE REPORT IS PROVIDED ON “AS IS” BASIS. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAWS, CRISIL RATINGS DISCLAIMS WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR OTHER WARRANTIES OR CONDITIONS, INCLUDING WARRANTIES OF MERCHANTABILITY, ACCURACY, COMPLETENESS, ERROR-FREE, NON-INFRINGEMENT, NON-INTERRUPTION, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE OR INTENDED USAGE. In no event shall CRISIL Ratings, its associates, third-party providers, as well as their directors, officers, shareholders, employees or agents be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

The report is confidential information of CRISIL Ratings and CRISIL Ratings reserves all rights, titles and interest in the rating report. The report shall not be altered, disseminated, distributed, redistributed, licensed, sub-licensed, sold, assigned or published any content thereof or offer access to any third party without prior written consent of CRISIL Ratings.

CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains or its associates. Ratings are subject to revision or withdrawal at any time by CRISIL Ratings. CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.

CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For more detail, please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the Securities and Exchange Board of India regulations (and other applicable regulations, if any), are made available on its websites, www.crisilratings.com and https://www.ratingsanalytica.com (free of charge). CRISIL Ratings shall not have the obligation to update the information in the CRISIL Ratings report following its publication although CRISIL Ratings may disseminate its opinion and/or analysis. Reports with more detail and additional information may be available for subscription at a fee.  Rating criteria by CRISIL Ratings are available on the CRISIL Ratings website, www.crisilratings.com. For the latest rating information on any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisilratings.com/en/home/our-business/ratings/credit-ratings-scale.html